TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
The Covax programme, which aims to provide two billion doses of vaccine, pools funding from richer countries with the intention of ensuring poorer nations can inoculate their health workers and most vulnerable citizens, on the basis that the pandemic would remain a global threat if it was not tackled worldwide.
Indonesia began its vaccination program on Wednesday using Chinese firm Sinovac Biotech's CoronaVac vaccine, which would be used on the largest share — or some 65 million — of the targeted 181.5 million Indonesians.
Sao Paulo’s Butantan biomedical center, which partnered with Sinovac to test and produce the vaccine in Brazil, dismissed the report as “purely speculative” as it prepares to release a more complete set of results on Tuesday.
